Our Vision and Mission
We are a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world.
Our mission is to harness transformative science and global partnerships to bring innovative vaccines to populations worldwide.
LEARN MORE>> 
                    Technology
We leverage the Trimer-Tag technology platform and our in-house manufacturing and commercial capabilities to develop innovative vaccines.
LEARN MORE>> 
                    Pipeline
We have a diverse pipeline of candidates with the potential to make a meaningful difference in improving health around the world.
LEARN MORE>> 
                    Response
We are expanding access to our COVID-19 vaccine and continuing to develop next-generation options as part of the ongoing response to COVID-19.
LEARN MORE>>Areas of Focus
 
                    
Vaccines
 
                    Other
Diseases
Latest News
- Oct 20, 2025 - Clover Appoints Nicholas Jackson, Ph.D., as President of Global R&D and Alliances 
- Oct 14, 2025 - Clover Announces Positive Phase I Clinical Data for RSV-hMPV-PIV3 Combination Vaccines and for RSV Re-Vaccination in Older Adults 
- Jun 17, 2025 - Clover Initiates Phase I Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates 
- Mar 24, 2025 - Clover Announces U.S. IND Clearance and Initiation of Revaccination Clinical Study for RSV Vaccine Candidate SCB-1019 
 
                 
                 
                 
                 
                


 
                             
                        